Document Type : Review Article(s)
Authors
1
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2
Assistance Professor, Medical Toxicology Research Center, faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3
Department of Medical Parasitology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4
student, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
5
PHD, Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
6
Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Science, Mashhad, Iran
7
Department of Pharmacodynamics & Toxicology, Faculty of pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
8
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
9
Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences,Mashhad, Iran
Abstract
Objectives: Pregabalin (PGB)-induced seizures (PGBIS) and their risk factors was systematically reviewed.
Methods:
The databases were searched from January 1, 2011 to August 1, 2022. Studies were included if they reported PGBIS. The recorded were assessed according PRISMA-P protocol.
Results:
Out of 224 records, 11 papers (4 cross-sectional studies and 7 case reports) were included. The cross-sectional studies reported very limited data. 9 cases (5 women and 4 men) with a median age of 51 years (16-65) were reported in 7 studies. PGB was used for therapeutic purposes, abuse, and suicide attempts. One case had kidney dysfunction. A significant number of cases used PGB with other drugs. There was no difference between the ingested dose of PGB in men (2700 and 4200 mg) and women (3000, 1200, 3825, and 1200 mg). Except one case, all cases had normal renal function.
Conclusions:
PGBIS is not common. but reported in all purpose of PGB consumption. None specific risk factor for PGBIS found. It was more commonly reported in females, patients who consumed high doses of PGB (>1200 mg), patients who ingested multiple drugs, and patients with renal insufficiency. The dosages used for therapeutic purposes were much lower than in the other two groups.
Keywords
)